NCT02863458View on ClinicalTrials.gov

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

September 1, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Trial Locations (1)

44195

Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT02863458 - DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US | Biotech Hunter | Biotech Hunter